Motley Fool Asset Management’s Axsome Therapeutics AXSM Stock Holding History

Motley Fool Asset Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$380K	Buy	+1,551	New	+$336K	0.01%	204

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

GIP

Granite Investment Partners El Segundo, California $1.95B AUM 49.89% 1-Year Est. Return

Motley Fool Asset Management's AXSM Position: Q2 2026 in Review

Motley Fool Asset Management opened a new position in Axsome Therapeutics (AXSM) in Q2 2026: 1,551 shares worth $380K. The stake represents 0.01% of the portfolio and ranks #204 among its holdings.

190 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

Motley Fool Asset Management held 1,551 shares of Axsome Therapeutics worth $380K as of Q2 2026.
Axsome Therapeutics was a new Motley Fool Asset Management position in Q2 2026.
Axsome Therapeutics made up 0.01% of Motley Fool Asset Management's portfolio in Q2 2026, its #204 holding.
190 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Motley Fool Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.